ChinaBio Today -- As China biopharma continues to evolve, the once dominant model of Western companies seeking opportunities in Asia, a uni-directional relationship, shows signs of giving way to increased bi-directional cooperation between West and East. In the last eighteen months, we have seen two large transactions in which fairly young China companies have made major acquisitions in the US. We expect this reciprocity to remain a trend, driven in part by an increasingly attractive US cost environment, particularly in real estate.
